SARA BENNETT: Open Payments
NPI 1104364173 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$10,881 in 88 payments from 12 companies in 2025. Trend: 2023 $481 · 2024 $947 · 2025 $10,881
Speaker / faculty: $7,560Food & beverage: $2,300Travel & lodging: $1,021
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 32 | $7,429 |
| Regeneron Healthcare Solutions, Inc. | 15 | $2,549 |
| AstraZeneca Pharmaceuticals LP | 9 | $281 |
| Ionis Pharmaceuticals, Inc. | 7 | $151 |
| GlaxoSmithKline, LLC. | 12 | $139 |
| Novartis Pharmaceuticals Corporation | 3 | $95 |
| BioCryst US Sales Co., LLC | 3 | $58 |
| CSL Behring | 2 | $55 |
| Galderma Laboratories, L.P. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $38 |
Products named: DUPIXENT, TEZSPIRE, DAWNZERA, NUCALA, FASENRA, ORLADEYO, Hizentra, NEMLUVIO.
Industry payments across GA — which companies pay providers there.
